Related Experiment Videos
Dihydroergocristine in stopping lactation: double-blind study vs bromocriptine
D de Aloysio1, F Pamparana, A Zanotti
1Department of Obstetrics and Gynecology, University of Bologna, Italy.
Summary
Dihydroergocristine effectively reduces prolactin levels and milk secretion in postpartum women compared to bromocriptine. This study highlights dihydroergocristine as a well-tolerated option for lactation suppression.
Area of Science:
- Endocrinology
- Pharmacology
- Obstetrics & Gynecology
Background:
- Lactation suppression is often necessary postpartum.
- Bromocriptine has been a standard treatment, but side effects can occur.
Purpose of the Study:
- To compare the efficacy and safety of dihydroergocristine with bromocriptine for lactation inhibition.
- To evaluate prolactin (PRL) levels, milk secretion, and side effects.
Main Methods:
- Double-blind, randomized study involving 30 women.
- Comparison of 10 mg dihydroergocristine vs. 2.5 mg bromocriptine for 5-10 days.
- Monitoring of PRL plasma levels, milk secretion, breast symptoms, and side effects.
Main Results:
- Both drugs significantly decreased prolactin levels (p < 0.01).
- Dihydroergocristine showed a more significant reduction in milk secretion after 5 days.
- Fewer treatment failures for milk secretion were observed with dihydroergocristine (1 vs. 6 cases).
- No significant breast congestion or pain in either group.
- Bromocriptine group experienced a significant decrease in systolic blood pressure; more gastrointestinal and neurological side effects were noted with bromocriptine.
Conclusions:
- Dihydroergocristine is an effective and potentially safer alternative to bromocriptine for suppressing lactation.
- Dihydroergocristine demonstrates superior efficacy in reducing milk secretion with fewer reported side effects.